« Cynologie/Insuffisance cardiaque canine » : différence entre les versions

Seul représentant sur le marché de la classe des inodilatateurs, le [[:de:Pimobendan|Pimobendan]]<ref>Bomassi E. Principe actif : le Pimobendane. Le Nouveau Praticien canine, féline 2007 Nov/Déc/Jan (552) :60-63</ref>{{,}}<ref>Fuentes VL, Corcoran B, French A, Schober KE, Kleemann R, Justus C. A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy. J Vet Intern Med. 2002 May-Jun;16(3):255-61.</ref>{{,}}<ref>Smith PJ, French AT, Van Israël N, Smith SG, Swift ST, Lee AJ, Corcoran BM, Dukes-McEwan J. Efficacy and safety of pimobendan in canine heart failure caused by myxomatous mitral valve disease. J Small Anim Pract. 2005 Mar;46(3):121-30.</ref>{{,}}<ref>Lombard CW, Jons O, Bussadori CM. Clinical efficacy of pimobendan versus benazepril for the treatment of acquired atrioventricular valvular disease in dogs. J Am Anim Hosp Assoc. 2006 Jul-Aug;42(4):249-61.</ref>{{,}}<ref name="note12">Kanno N, Kuse H, Kawasaki M, Hara A, Kano R, Sasaki Y. Effects of pimobendan for mitral valve regurgitation in dogs. J Vet Med Sci. 2007 Apr;69(4):373-7.</ref>{{,}}<ref name="note13">Ouellet M, Difruscia R, Bélanger MC. Evaluation of pimobendan in the treatment of early mitral valve disease. J Vet Intern Med. 2007;21:610.</ref>{{,}}<ref>Richard Woolley, Paul Smith, Elizabeth Munro, Sarah Smith, Simon Swift, Craig Devine, Brendan Corcoran, Anne French. Effects of Treatment Type on Vertebral Heart Size in Dogs With Myxomatous Mitral Valve Disease. Intern J Appl Res Vet Med. 2007;5 (1):43-8</ref>{{,}}<ref>US FDA. [http://www.fda.gov/OHRMS/DOCKETS/98fr/2007-141-273-fois001.pdf FOI Vetmedin Chewable Tablets - NADA 141-273, 30 Apr. 2007] </ref>{{,}}<ref>A.C. Vollmar, C. Trötschel, R. Kleemann, P.R. Fox. Clinical efficacy of pimobendan in comparison to benazepril and metildigoxin in irish wolfhounds with preclinical DCM; preliminary evaluation of an ongoing study after 6 years. J Vet Intern Med 2007;21:1420–1445</ref>{{,}}<ref>C.P. Sturgess, L. Ferasin. Clinical efficacy of pimobendan in 11 cats with systolic heart failure. J Vet Intern Med 2007;21:1420–1445</ref>{{,}}<ref name="Dobermann">M.R. O’Grady, S.L. Minors, M.L. O’Sullivan, and R. Horne. Effect of Pimobendan on Case Fatality Rate in Doberman Pinschers with Congestive Heart Failure Caused by Dilated Cardiomyopathy. J Vet Intern Med 2008;22:897–904.</ref>{{,}}<ref name="Quest">Häggström J et al. Effect of Pimobendan or Benazepril Hydrochloride on Survival Times in Dogs with Congestive Heart Failure Caused by Naturally Occurring Myxomatous Mitral Valve Disease: The QUEST Study. J Vet Intern Med 2008;22:1124-1135</ref>{{,}}<ref name="Ouellet">M. Ouellet, M.C. Bélanger, R. DiFruscia, and G. Beauchamp. Effect of Pimobendan on Echocardiographic Values in Dogs with Asymptomatic Mitral Valve Disease. J Vet Intern Med 2009;[early online]</ref> (''Vetmedin''®, [[Boehringer-Ingelheim Pharmaceuticals|Boehringer Ingelheim]]) semble devoir devenir le traitement de choix de première intention de l’insuffisance cardiaque congestive.

 

 

Le pimobendane est enregistré en Europe, au Canada et aux États-Unis pour le traitement de l’insuffisance cardiaque congestive liée à une MVD ou à une CMD. C’est actuellement la seule molécule inotrope positive utilisable au long cours.